HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at HC Wainwright boosted their FY2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.00) per share for the year, up from their prior estimate of ($1.04). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.82) EPS.

A number of other brokerages also recently issued reports on RVPH. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday. Roth Mkm began coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Stock Up 1.1 %

NASDAQ RVPH opened at $1.91 on Friday. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83. The firm has a 50-day moving average price of $1.71 and a 200 day moving average price of $1.33. The stock has a market capitalization of $63.87 million, a P/E ratio of -1.72 and a beta of -0.12.

Institutional Trading of Reviva Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after buying an additional 42,376 shares during the last quarter. EMC Capital Management increased its holdings in Reviva Pharmaceuticals by 142.0% during the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after acquiring an additional 26,134 shares in the last quarter. Finally, Drive Wealth Management LLC acquired a new position in Reviva Pharmaceuticals during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.